<em>Nesfatin</em>-<em>1</em>/NUCB2, which is associated with the control of appetite and energy metabolism, was reported for the first time to be expressed in the hypothalamus. However, recent studies have shown that <em>nesfatin</em>-<em>1</em>/NUCB2 was expressed not only in the hypothalamus, but also in various tissues including digestive and reproductive organs. We also demonstrated that <em>nesfatin</em>-<em>1</em>/NUCB2 was expressed in the reproductive organs, pituitary gland, heart, lung, and gastrointestinal tract of the adult mouse. However, little is known about <em>nesfatin</em>-<em>1</em>/NUCB2 expression in fetal and neonatal mice. Therefore, we examined here the distribution of <em>nesfatin</em>-<em>1</em>/NUCB2 in various organs of fetal and neonatal mice and compared them with the distribution in adult mice. As a result of immunohistochemical staining, <em>nesfatin</em>-<em>1</em>/NUCB2 protein was expressed relatively higher in the lung, kidney, heart, and liver compared to other organs in the fetus. Western blot results also showed that <em>nesfatin</em>-<em>1</em>/NUCB2 protein was detected in the lung, kidney, heart, and stomach. Next, we compared the expression levels of <em>nesfatin</em>-<em>1</em>/NUCB2 mRNA in the fetus and neonate with the expression levels in both male and female adult mice. The expression levels in heart, lung, stomach, and kidney were higher compared with other organs in fetal and neonatal mice and in both male and female adult mice. Interestingly, the expression of <em>nesfatin</em>-<em>1</em>/NUCB2 mRNA in the kidney was devrepamatically increased in male and female adult mice compared to fetal and neonatal mice. These results indicate that <em>nesfatin</em>-<em>1</em>/NUCB2 may regulate the development and physiological function of mouse organs. In the future, we need more study on the function of <em>nesfatin</em>-<em>1</em>/NUCB2, which is highly expressed in the heart, lung, and kidney during mouse development.

The aim of this work was to determine if the anorexigen <em>nesfatin</em>-<em>1</em> modulates the expression of genes involved in glucoregulation in rainbow trout. First, the <em>nesfatin</em>-<em>1</em> sequence from trout was confirmed. Second, the effects of 0.<em>1</em>, <em>1</em> and <em>1</em>0 nM <em>nesfatin</em>-<em>1</em> on insulin, glucagon, igf-I, igf-II, glut<em>1</em>, glut2, glut4 and sglt<em>1</em> expression were tested in cultured liver, gut, muscle and adipose tissue. In liver, the expression of insulin and glucagon isoforms X<em>1</em> increased after 2 h of incubation with 0.<em>1</em> nM <em>nesfatin</em>-<em>1</em>, while insulin and glucagon X2 expression increased after 4 h with <em>1</em> nM treatment. All <em>nesfatin</em>-<em>1</em> doses tested decreased glut2 expression after 4 h. In adipose tissue, all <em>nesfatin</em>-<em>1</em> concentrations reduced insulin X<em>1</em> expression at 30 min, and <em>1</em> nM <em>nesfatin</em>-<em>1</em> increased insulin X2 expression at 4 h. In gut, 0.<em>1</em>, <em>1</em> and <em>1</em>0 nM <em>nesfatin</em>-<em>1</em> decreased glut2 and sglt<em>1</em> mRNA levels after 240 min of incubation. In muscle, 0.<em>1</em> nM <em>nesfatin</em>-<em>1</em> increased the expression of igf-I after 240 min. The expression of igf-II in muscle increased after 30 min of incubation with <em>1</em> and <em>1</em>0 nM <em>nesfatin</em>-<em>1</em> and after <em>1</em>20 min of incubation with 0.<em>1</em> and <em>1</em> nM <em>nesfatin</em>-<em>1</em>. Expression of glut<em>1</em> and sglt<em>1</em> in muscle increased after 240 min of incubation with 0.<em>1</em> nM <em>nesfatin</em>-<em>1</em> and after <em>1</em>20 min with 0.<em>1</em> and <em>1</em>0 nM <em>nesfatin</em>-<em>1</em>, respectively. These results suggest that <em>nesfatin</em>-<em>1</em> could decrease the gut intake of dietary glucose, and increase its uptake in glucoregulatory tissues such as liver and muscle of rainbow trout.

Peripheral anorectic hormones, such as peptide YY (PYY) and oxytocin (OXT), suppress food intake. A newly identified anorectic neuropeptide, <em>nesfatin</em>-<em>1</em>, is synthesized in both peripheral tissue and the central nervous system, particularly by various nuclei in the hypothalamus and brainstem. Here, we examined the effects of intraperitoneal (ip) administration of PYY3-36, OXT, and OXT analog, on <em>nesfatin</em>-<em>1</em>-immunoreactive (ir) neurons in the rat hypothalamus and brainstem, using Fos double fluorescence-immunohistochemistry. The ip administration of OXT and OXT analog significantly increased the number of <em>nesfatin</em>-<em>1</em>-ir neurons expressing Fos-ir in the paraventricular nucleus, the arcuate nucleus, and the nucleus tractus solitarius, but not in the supraoptic nucleus, the lateral hypothalamic area, and the area postrema. No differences in the percentage of <em>nesfatin</em>-<em>1</em>-ir neurons expressing Fos in the nuclei of the hypothalamus and brainstem were observed, between rats treated with vehicle or those treated with PYY3-36. The decreased food intake, induced by OXT and OXT analog, was attenuated significantly by pretreatment with intracerebroventricular administration of antisense <em>nesfatin</em>-<em>1</em>. These results suggested that <em>nesfatin</em>-<em>1</em>-expressing neurons in the hypothalamus and brainstem may play a role in sensing the peripheral level of OXT and its suppression of feeding in rats.

<AbstractText>The aim of the study was to determine the effect of <em>nesfatin</em>-<em>1</em> on bone properties in female rats in the conditions of developing osteopenia induced by ovariectomy (OVX).</AbstractText><AbstractText>The experiment was performed on 2<em>1</em> female Wistar rats assigned to 3 groups receiving intraperitoneally physiological saline (SHO, OVX-PhS) and <em>nesfatin</em>-<em>1</em> in dose 2 μg/kg BW of (OVX-NES) once a day for 8 wks. At the end of the experiment, the rats were scanned using the DXA method to determine the body composition, tBMC, and tBMD. The isolated femora and tibia were tested with the DXA method for BMD and BMC, and with the pQCT method for separate analysis of the cortical and trabecular bone tissue. The bone strength parameters were also determined. The immunohistochemical method was used for determination of <em>nesfatin</em>-<em>1</em> localization in growth cartilage. Bone metabolism markers (osteocalcin, bALP, and NTx) were identified using an ELISA kit.</AbstractText><AbstractText>OVX exerts a negative effect on bone tissue. The <em>nesfatin</em>-<em>1</em> administration influenced positively the DXA parameters of tibia. TvBMD and TbvBMD measured by pQCT in metaphysis of bones were significantly higher in the OVX-NES group than in OVX-PhS. No differences were found in the values of bone strength parameters between SHO and OVX-NES females. Extra- and intracellular immunohistochemical reaction for <em>nesfatin</em>-<em>1</em> was observed in all zones of growth cartilage, with the strongest reaction detected in the calcifying zone. <em>Nesfatin</em>-<em>1</em> administration caused a significant increase in the osteocalcin and bALP concentration in relation to the OVX-PhS animals.</AbstractText><AbstractText>The results of the experiment indicate that <em>nesfatin</em>-<em>1</em> exerts a protective effect on bone tissue properties and can be used in the prevention of osteoporosis.</AbstractText>

OBJECTIVE

In this study, we aim to reveal the alterations (due to seizure) in the serum and brain levels of <em>nesfatin</em>-<em>1</em>, ghrelin and irisin after acute or chronic pentylenetetrazole administrations in rats using sodium valproate.

METHODS

35 Wistar albino rats were randomly divided into five groups: Control, Acute Pentylenetetrazole group (APTZ), Acute Pentylenetetrazole+ Valproate group (AVPA), PTZ kindling group (PTZk) and PTZ kindling+ Valproate group (KVPA). Serum and brain levels of ghrelin, <em>nesfatin</em>-<em>1</em> and FNDC5/irisin were determined with ELISA.

RESULTS

Serum levels of ghrelin were significantly decreased in APTZ and PTZk groups compared to the control (p < 0.0<em>1</em>). There was a statistically significant decrease in brain levels of ghrelin in all groups compared to the control group (p < 0.0<em>1</em>). There was a statistically significant increase in serum <em>nesfatin</em>-<em>1</em> levels in the APTZ and PTZk groups compared to the control (p < 0.05). Serum levels of <em>nesfatin</em>-<em>1</em> were similar to the control group in both the acute and the chronic treatment groups. There was a statistically significant increase in brain <em>nesfatin</em>-<em>1</em> levels of the KVPA group compared to the control (p < 0.05). Serum and brain levels of FNDC5/irisin were found significantly increased in APTZ, AVPA and PTZk groups compared to the control (p < 0.0<em>1</em>).

CONCLUSIONS

Statistically significant alterations were detected in the serum and brain levels of these three peptides in both the PTZ-induced chronic epilepsy model and acute seizure model. The results of this study may suggest that the increase in FNDC5/irisin and <em>nesfatin</em>-<em>1</em> levels, and the decrease in ghrelin levels may contribute to seizure pathophysiology. However, further studies are needed in order to confirm our hypothesis.

<em>Nesfatin</em>-<em>1</em> and ghrelin are two hormones which has opposite effects and play role in food intake. This study was planned on the idea that both metabolic syndrome and psychiatric disorders are associated with <em>nesfatin</em>-<em>1</em> and ghrelin. In this study, it was aimed to investigate the levels of ghrelin and <em>nesfatin</em>-<em>1</em> in patients with schizophrenia, by taking confounding factor as the metabolic syndrome (MS). 55 patients with schizophrenia and 33 healthy controls were included in the study.<em>1</em><em>1</em> out of the 55 patients (%20) has MS. Serum ghrelin and <em>nesfatin</em>-<em>1</em> levels of schizophrenia patients with MS have been compared with both healthy controls and schizophrenia patients without MS. Patients with schizophrenia had significantly higher serum <em>nesfatin</em>-<em>1</em> levels compared to healthy controls. But serum ghrelin levels was not different in both groups. Serum <em>nesfatin</em>-<em>1</em> concentrations were significantly higher in the schizophrenia patients with MS (<em>1</em>0.5<em>1</em>-350.8pg/ml) with respect to the healthy control group (4.86-68.9<em>1</em>pg/ml). There was no significant statistical difference between the three groups in terms of ghrelin levels. Our findings suggests that, MS presence also contributed to significantly high levels of <em>nesfatin</em>-<em>1</em> level. <em>Nesfatin</em>-<em>1</em> may have a part in a novel studies regarding the treatment of schizophrenia and its metabolic effects.

Pejerrey, Odontesthes bonariensis, is an euryhaline fish of commercial importance in Argentina. This work aimed to determine if water salinity affects the expression of genes involved in somatic growth (gh; ghr-I; ghr-II; igf-I), lipid metabolism (Δ6-desaturase) and food intake (nucb2/<em>nesfatin</em>-<em>1</em>). First, we identified the full-length cDNA sequences of Δ6-desaturase (involved in lipid metabolism) and <em>nesfatin</em>-<em>1</em> (an anorexigen). Then, pejerrey juveniles were reared during 8weeks in three different water salinity conditions: 2.5g/L (S2.5), <em>1</em>5g/L (S<em>1</em>5) and 30g/L (S30) of NaCl. Brain, pituitary, liver and muscle samples were collected in order to analyze mRNA expression. The expression of gh and ghr-II mRNAs increased in the pituitary of fish reared at S2.5 and S30 compared with the S<em>1</em>5 group. The expression of ghr-I was higher in the liver of S30 group compared to S2.5 and S<em>1</em>5. Igf-I mRNA expression in liver increased with the increment of water salinity, while it decreased in the muscle of S<em>1</em>5 and S30 groups. Δ6-desaturase expression increased in S2.5 group compared to S<em>1</em>5 in both liver and muscle. S30 caused a decrease in the Δ6-desaturase expression in liver compared to S<em>1</em>5. The S30 treatment produced an increase in nucb2/<em>nesfatin</em>-<em>1</em> mRNA expression in the brain and liver compared to S2.5 and S<em>1</em>5. The changes in gene expression observed could help pejerrey perform better during salinity challenges. The S30 condition would likely promote pejerrey somatic growth in the long term.

<em>Nesfatin</em>-<em>1</em> is an 82-amino acid protein derived from nucleobindin 2 (NUCB2), which could inhibit food intake in fish and mammals. However, the neuroendocrine mechanism of <em>nesfatin</em>-<em>1</em> in animal appetite regulation is unclear. To explore the feeding mechanism of <em>nesfatin</em>-<em>1</em> in Siberian sturgeon (Acipenser baerii), intraperitoneal injections of <em>nesfatin</em>-<em>1</em> and sulfated cholecystokinin octapeptide (CCK8), Lorglumide (CCK<em>1</em>R selective antagonist), or LY 225,9<em>1</em>0 (CCK2R selective antagonist) were performed. Co-injection of <em>nesfatin</em>-<em>1</em> and CCK8 synergistically significantly decreased the food intake in <em>1</em> h. Lorglumide reversed the anorectic effect of <em>nesfatin</em>-<em>1</em>, but LY 225,9<em>1</em>0 had no effect. Moreover, Lorglumide could also reverse the expressions of appetite factors including nucb2, cck, unc3, cart, apelin, pyy, and npy induced by <em>nesfatin</em>-<em>1</em> in the brain, stomach, and liver, while LY 225,9<em>1</em>0 partially reversed these changes. These results indicate that <em>nesfatin</em>-<em>1</em> inhibits the appetite of Siberian sturgeon mainly through the CCK-CCK<em>1</em>R signaling pathway.

OBJECTIVE

To investigate the expression of <em>nesfatin</em>-<em>1</em>/NUCB2 and ghrelin in the gastric mucosa of rats with intrauterine growth retardation (IUGR) and its significance.

METHODS

The IUGR animal model was established by feeding rats low-protein diets during their pregnancy. Newborn rats were divided into catch-up growth, non-catch-up growth and control groups. Protein and mRNA levels of <em>nesfatin</em>-<em>1</em>/NUCB2 and ghrelin in the gastric mucosa of rats were determined by RT-PCR and Western blot, respectively.

RESULTS

Nesfatin-<em>1</em>/NUCB2 mRNA and protein were expressed in the gastric mucosa of rats immediately after birth, and their expression increased in an age-dependent manner in all three groups. Furthermore, the level of <em>nesfatin</em>-<em>1</em>/NUCB2 in the catch-up growth group was higher than that in the control group before weaning, whereas there was no significant difference in <em>nesfatin</em>-<em>1</em>/NUCB2 expression between the two groups after weaning. The level of <em>nesfatin</em>-<em>1</em>/NUCB2 in the non-catch-up growth group was lower than that in the catch-up growth group during the whole observation period. The level of ghrelin in the catch-up growth group was higher than that in the control group starting from day <em>1</em>2 after birth, whereas there was no significant difference in ghrelin expression between the two groups after weaning. The level of ghrelin in the non-catch-up growth group was lower compared with those in the catch-up growth and control groups from days <em>1</em>2 to 28 after birth.

CONCLUSIONS

Nesfatin-<em>1</em> and ghrelin are co-expressed in the gastric mucosa of rats with IUGR after birth and interact with each other to produce long-term nutritional regulation.

Background Changes in thyroid hormone concentrations may affect adiponectin concentrations through various mechanisms. A molecule released primarily from the fat cells adiposities; adiponectin has important effects on the regulation of body weight. Aim The present study aimed to explore the effects of experimental thyroid dysfunction and its treatment on <em>nesfatin</em>-<em>1</em> and adiponectin levels in rats. Methods The study included 40 adult male Sprague-Dawley rats which were grouped as follows: (<em>1</em>) control; (2) hypothyroidism [hypothyroidism was induced by intraperitoneal injection of <em>1</em>0 mg/kg/day propylthiouracil (PTU) for 3 weeks]; (3) hypothyroidism + thyroxine group [after hypothyroidism was induced by 2-week PTU injection, they were treated with high-dose L-thyroxine (<em>1</em>.5 mg/kg/day) for <em>1</em> week]; (4) hyperthyroidism [hyperthyroidism was induced by 3-weeks' thyroxine injection (0.3 mg/kg/day)]; (5) hyperthyroidism + PTU (after hyperthyroidism was induced by 2-weeks' thyroxine injection, the animals were given <em>1</em>0 mg/kg/day PTU for <em>1</em> week). Blood samples taken at the end of the study were analyzed to measure <em>nesfatin</em>-<em>1</em> and adiponectin levels. Results It was found that <em>nesfatin</em>-<em>1</em> levels increased in hypothyroidism, while adiponectin levels decreased (p < 0.00<em>1</em>). In experimental hyperthyroidism, on the other hand, both <em>nesfatin</em>-<em>1</em> and adiponectin levels were found significantly elevated (p < 0.00<em>1</em>). Conclusion The results of the study indicate that <em>nesfatin</em>-<em>1</em> and adiponectin levels were modified considerably in hypo- and hyperthyroidism, whereas with the restoration of the thyroid function, modified hormone levels went back to normal.

Despite the increasing amount of evidence suggesting a relationship between depression and subclinical hypothyroidism (SCH), the exact mechanism underlying this relationship remains unclear. The main purpose of this study was to investigate the roles of plasma <em>Nesfatin</em>-<em>1</em> levels and dysfunction of the hypothalamic-pituitary-adrenal (HPA) and hypothalamus-pituitary-thyroid (HPT) axes in the comorbidity of depression and SCH. Dysfunctions of the HPA and HPT axes were detected by measuring plasma corticosterone and thyroid-stimulating hormone (TSH) concentrations, respectively. Subjects in the patient group were selected from patients hospitalized at the Anhui Mental Health Center, and subjects in the control group were recruited from healthy volunteers. Healthy control subjects were matched to the patients in terms of weight and body mass index. The Hamilton Depression Rating Scale was administered to both the groups. The enzyme-linked immunosorbent assay method was used to measure plasma <em>Nesfatin</em>-<em>1</em>, corticosterone, and TSH levels. A radioimmunoassay kit was used for the measurement of the plasma-free triiodothyronine and plasma-free thyroxine. The results showed that the Hamilton Depression Rating Scale scores and average <em>Nesfatin</em>-<em>1</em>, corticosterone, and TSH levels were significantly higher in depressed patients with SCH than in the control group. Moreover, positive relationships were observed between <em>Nesfatin</em>-<em>1</em> levels and the concentrations of corticosterone (r=0.626, P<0.00<em>1</em>) and TSH (r=0.229, P=0.036) in depressed patients with SCH. These findings indicate that <em>Nesfatin</em>-<em>1</em> is involved in the comorbidity of depression and SCH, and the mechanism underlying this involvement might be related to the dysfunction of the HPA and HPT axes.

<AbstractText><em>Nesfatin</em>-<em>1</em> is an antiiflammatory, antiapoptotic, and anorexigenic peptide that has many roles in cardiomyocyte metabolism and viability. Inflammation plays an important role in the pathogenesis of atherosclerosis. In this study, we aimed to evaluate the alterations in serum <em>nesfatin</em>-<em>1</em> levels of the patients undergoing coronary artery bypass operation due to atherosclerotic coronary artery disease.</AbstractText><AbstractText>The study included 49 patients (30 men, <em>1</em>9 women) undergoing coronary artery bypass surgery. Serum <em>nesfatin</em>-<em>1</em> levels were measured from venous blood samples of the patients collected before and three months after the operation. The relationship of <em>nesfatin</em>-<em>1</em> levels with accompanying conditions was also analyzed.</AbstractText><AbstractText><em>Nesfatin</em>-<em>1</em> levels at third month, postoperatively, were significantly higher than preoperative <em>nesfatin</em>-<em>1</em> levels of the patients (4<em>1</em>.94±<em>1</em>3.90 pg/ml and 27.06±8.0<em>1</em>pg/ml, respectively; p<0.00<em>1</em>). Both preoperative and postoperative <em>nesfatin</em>-<em>1</em> levels were negatively correlated with age (p<0.00<em>1</em>). The postoperative increase in <em>nesfatin</em>-<em>1</em> levels was significantly higher in diabetic patients than in nondiabetic patients (p<0.00<em>1</em>).</AbstractText><AbstractText>This study revealed that serum <em>nesfatin</em>-<em>1</em> levels increased significantly in patients undergoing coronary artery bypass operation. <em>Nesfatin</em>-<em>1</em> level may have a role in assessing myocardial perfusion during the follow-up of these patients (Tab. 4, Fig. 4, Ref. 25).</AbstractText>

BACKGROUND

<em>Nesfatin</em>-<em>1</em>, a recently identified satiety molecule derived from nucleobindin 2 (NUCB2), is associated with visceral hypersensitivity in rats and is expressed in the amygdala. We tested the hypothesis that <em>nesfatin</em>-<em>1</em> expression in the amygdala is involved in the pathogenesis of irritable bowel syndrome (IBS) visceral hypersensitivity.

METHODS

An animal model of IBS-like visceral hypersensitivity was established using maternal separation (MS) during postnatal days 2-<em>1</em>6. The role of <em>nesfatin</em>-<em>1</em> in the amygdala on visceral sensitivity was evaluated.

RESULTS

Rats subjected to MS showed a significantly increased mean abdominal withdrawal reflex (AWR) score and electromyographic (EMG) activity at 40, 60, and 80 mmHg colorectal distension. Plasma concentrations of <em>nesfatin</em>-<em>1</em> and corticosterone were significantly higher than in non-handled (NH) rats. mRNA and protein expression of <em>nesfatin</em>-<em>1</em>/NUCB2 in the amygdala were increased in MS rats, but not in NH rats. In MS rats, AWR scores and EMG activity were significantly decreased after anti-<em>nesfatin</em>-<em>1</em>/NUCB2 injection. In normal rats, mean AWR score, EMG activity, and corticosterone expression were significantly increased after <em>nesfatin</em>-<em>1</em> injection into the amygdala. <em>Nesfatin</em>-<em>1</em>-induced visceral hypersensitivity was abolished following application of glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) antagonists.

CONCLUSIONS

Elevated expression of <em>nesfatin</em>-<em>1</em>/NUCB2 in the amygdala in MS rats suggests a potential role in the pathogenesis of visceral hypersensitivity, which could potentially take place via activation of GR and MR signaling pathways.

<strong class="sub-title"> Background: </strong> We investigated the effects of spirulina under high-intensity interval training (HIIT) on levels of <em>nesfatin</em>-<em>1</em>, omentin-<em>1</em>, and lipid profiles in overweight and obese females.

<strong class="sub-title"> Materials and methods: </strong> This is a randomized, quasi-experimental controlled, single-blind with a pre- and post-test design, in which twenty overweight and obese women (body mass index = 29.32 ± 3.0<em>1</em> kg/m², age = 2<em>1</em>.55 ± <em>1</em>.76 years), were randomly divided into the following groups: HIIT + spirulina (<i>n</i> = <em>1</em>0) and HIIT + placebo (<i>n</i> = <em>1</em>0). Running anaerobic sprint test was used for HIIT protocol consisting of six intervals at 35 m maximal speed runs, with a rest of <em>1</em>0 s in each trial (3 times/week, 4 weeks). HIIT + spirulina group received 500 mg of the spirulina pills twice daily for 4 weeks and the second group took placebo.

<strong class="sub-title"> Results: </strong> There was a significant increase in serum levels of <em>nesfatin</em>-<em>1</em> in HIIT + spirulina (<i>P</i> < 0.000<em>1</em>) but not in HIIT + placebo (<i>P</i> = 0.6<em>1</em>) group. Furthermore, results indicated a significant difference between two groups with respect to serum levels of <em>nesfatin</em>-<em>1</em> (<i>P</i> = 0.04). Serum levels of omentin-<em>1</em> significantly increased in both groups (<i>P</i> < 0.05). However, there was no significant difference between two groups (<i>P</i> = 0.49). In addition, results showed no significant inter- and intra-group differences in total cholesterol levels, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol between groups (<i>P</i> > 0.05).

<strong class="sub-title"> Conclusion: </strong> The spirulina under HIIT increased levels of <em>nesfatin</em>-<em>1</em> and omentin-<em>1</em> with no effects on the levels of lipid profiles in overweight and obese females.

<strong class="sub-title"> Keywords: </strong> High-intensity interval training; lipid profiles; <em>nesfatin</em>-<em>1</em>; obese; omentin-<em>1</em>; spirulina.

<b>Objective:</b> This study aims to review the alteration of plasma <em>nesfatin</em>-<em>1</em> levels in patients with depression.<b>Methods:</b> Under the guidance of the latest PRISMA checklist, a systematic review and meta-analysis were conducted by searching English database (PubMed, Web of Science, EMDASE)and Chinese database for relevant studies up to August, 20<em>1</em>9. Pooled standardized mean difference (SMD) with 95% confidence intervals (CI) was calculated with the random effects model.<b>Results:</b> Nine studies that reported the association between plasma levels of <em>nesfatin</em>-<em>1</em> and the risk of depression with 567 patients and 447 control participants were included in the meta-analysis. Compared with the healthy controls, depressive patients had a higher plasma level of <em>nesfatin</em>-<em>1</em> [SMD (95% CI):<em>1</em>.58(0.75, 2.4<em>1</em>), Z = 3.74, <i>P</i> for Z < 0.00<em>1</em>; I² = 96.8%, <i>P</i> for I²< 0.00<em>1</em>]. The subgroup analyses and meta-regression failed to find the source of the heterogeneity. No evidence of publication bias was found either in Begg's test (<i>P</i> = 0.348) or the Egger's test (<i>P</i> = 0.523).<b>Conclusion:</b> The present meta-analysis indicated that a higher plasma level of <em>nesfatin</em>-<em>1</em> was associated with an increased risk of depression.

That <em>nesfatin</em>-<em>1</em> is a neuromodulatory peptide for the cardiovascular system is well documented. Several central receptors have been shown to mediate the cardiovascular effects of <em>nesfatin</em>-<em>1</em>. Immunohistochemistry and Western blot studies showed that <em>nesfatin</em>-<em>1</em> activated the expression of the central cyclooxygenase (COX) -<em>1</em>, -2 and lipoxygenase (LOX). In addition, microdialysis study showed that <em>nesfatin</em>-<em>1</em> increased the release of total prostaglandins and leukotrienes from the hypothalamus. The present study investigated whether the central COX and LOX enzymes have a direct mediating role in the MAP and HR responses of <em>nesfatin</em>-<em>1</em>. Intracerebroventricularly administered <em>nesfatin</em>-<em>1</em> produced dose-dependent pressor and phasic HR responses in normotensive conscious rats Sprague Dawley. Central pretreatment with a COX<em>1</em>/2 inhibitor, ibuprofen, completely blocked the <em>nesfatin</em>-<em>1</em>-induced responses. However, central pretreatment with a nonselective LOX inhibitor, nordihydroguaiaretic acid, partially attenuated the cardiovascular responses induced by <em>nesfatin</em>-<em>1</em>. The results suggest that centrally administered <em>nesfatin</em>-<em>1</em> activates the central enzymes COX and LOX, which may be involved in the cardiovascular responses as a novel central mechanism for <em>nesfatin</em>-<em>1</em>.

<strong class="sub-title"> Keywords: </strong> Cyclooxygenase; Heart rate; Intracerebroventricular; Lipoxygenase; Mean arterial blood pressure; Nesfatin-<em>1</em>.

We discovered a new anorexigenic protein, <em>nesfatin</em>/nucleobindin-2 (NUCB2), which includes an EF-hand, calcium-binding motif. <em>Nesfatin</em>/NUCB2 is converted to <em>nesfatin</em>-<em>1</em>, which may be a physiologically active form in the body. Centrally and systemically administered <em>nesfatin</em>-<em>1</em> inhibits appetite and body weight gain in rodents. The mid-segment of <em>nesfatin</em>-<em>1</em> appears to be important in the inhibition of food intake. Intranasal administration of the mid-segment inhibits appetite. <em>Nesfatin</em>-<em>1</em> may also be involved in the regulation of gastrointestinal function and insulin secretion. We have summarized the recent progress in the research of <em>nesfatin</em>-<em>1</em>.

Aim of study - examine the association between circulating blood adipokine levels (adiponectin, resistin, irisin, <em>nesfatin</em>-<em>1</em>, apelin-<em>1</em>2 and obestatin) and hypertension and obesity.; The study included a comprehensive survey of 98 patients, including 52 subjects with hypertension and 46 with hypertension and obesity. The levels of adiponectin, resistin, irisin, <em>nesfatin</em>-<em>1</em>, apelin-<em>1</em>2, obestatin has been determined.; On conducting an analysis of the study population, the circulating level of resistin (<em>1</em>9.32±0.53 ng/mL vs. <em>1</em>4.90±0.29 ng/mL, p=0.0024) was higher in obese subjects with hypertension than in those without obesity, whereas apelin-<em>1</em>2 (<em>1</em>.5<em>1</em>±0.09 ng/mL vs. <em>1</em>.42±0.04 ng/mL, p=0.069) and obestatin (2.97±0.04 ng/mL vs. 3.06±0.04 ng/mL, p=0.073) levels were not different between the two groups. The circulating levels of adiponectin (6.83±0.<em>1</em>0 ng/mL vs. 2.54±0.72 ng/mL, p=0.00038), irisin (<em>1</em>.9<em>1</em>±0.06 ng/mL vs. <em>1</em>.<em>1</em>9±0.03 ng/mL, p=0.02<em>1</em>) and <em>nesfatin</em>-<em>1</em> (8.07±0.06 ng/mL vs. 6.95±0.04 ng/mL, p=0.0057) were higher in subjects with hypertension than in those with obesity.; Patients in the highest tertile of resistin were more likely to have obesity and subjects in the highest tertile of adiponectin and <em>nesfatin</em>-<em>1</em> were more likely to have hypertension. Apelin-<em>1</em>2 and obestatin levels in plasma did not differ according to the presence or absence of obesity. The fact that the level of resistin is highest in patients with hypertension and obesity in comparison with patients with hypertension without obesity, and the level of adipokines such as adiponectin, <em>nesfatin</em>-<em>1</em> and irisin is higher in patients with hypertension without obesity in comparison with patients with hypertension and obesity may indicate a possible different pathogenetic role of the studied adipokines in the development of cardiovascular diseases. Since the cellular and molecular mechanisms of these changes are not definitively established and there are conflicting data in the literature, further research is needed to clarify the mechanisms of the pathogenetic role of the studied adipokines in the development of cardiovascular diseases.

OBJECTIVE

To investigate the effects of <em>nesfatin</em>-<em>1</em> on gastric function in obese rats.

METHODS

The obese rat model was induced by a high-fat diet. The gastric emptying rate and gastric acid secretory capacity of the rats were determined after treatment with different drug concentrations of <em>nesfatin</em>-<em>1</em> and administration routes. Based on this, the expression of H+/K+-ATPase was measured using RT-PCR and western blot to preliminarily explore the mechanism of gastric acid secretion changes.

RESULTS

Body weight, body length, and Lee's index of the rats significantly increased in the high-fat diet-induced obese rat model. Two hours after lateral intracerebroventricular injection of <em>nesfatin</em>-<em>1</em>, the gastric emptying rate and gastric acid secretory capacity of rats decreased. Four hours after injection, both were restored to normal levels. In addition, the expression of H+/K+-ATPase decreased and moved in line with changes in gastric acid secretory capacity. This in vivo experiment revealed that intracerebroventricular injection of <em>nesfatin</em>-<em>1</em>, rather than intravenous injection, could suppress gastric function in obese rats. Moreover, its effect on the gastric emptying and gastric acid secretory capacity of rats is dose-dependent within a certain period of time.

CONCLUSIONS

Through this research, we provide a theoretical basis for further studies on <em>nesfatin</em>-<em>1</em>, a potential anti-obesity drug.

<em>Nesfatin</em>-<em>1</em>, a recently discovered anorexigenic neuropeptide, seems to play an important role in hypothalamic pathways regulating food intake and energy homeostasis. The aim of this study was to evaluate the relation of serum <em>nesfatin</em>-<em>1</em> level with metabolic and anthropometric parameters in children and adolescents.This study prospectively included 78 Korean children and adolescents (42 obese/overweight group and 36 healthy control group). Fasting serum <em>nesfatin</em>-<em>1</em> was quantitatively assayed by ELISA. Lipid profile, fasting blood glucose, fasting insulin, and the homeostasis model assessment of insulin resistance (HOMA-IR) were measured as metabolic parameters.Serum <em>nesfatin</em>-<em>1</em> levels were significantly lower in obese/overweight group than in control group (median <em>1</em>.4 vs 2.0 ng/mL; P = .003). Pubertal subjects have the lower serum <em>nesfatin</em>-<em>1</em> level than pre-pubertal subjects (median <em>1</em>.5 vs 2.6 ng/mL; P = .02). <em>Nesfatin</em>-<em>1</em> levels negatively correlated with chronological age (r = -0.37; P = .00<em>1</em>), BMI (r = -0.33; P = .003), and BMI SDS (r = -0.26; P = .02).In conclusion, our results suggest that serum <em>nesfatin</em>-<em>1</em> negatively correlated with BMI in children and adolescents. It suggests that <em>nesfatin</em>-<em>1</em> might have an important role in regulation of food intake in obese children and adolescents.